Donate Now
Home | News | Events | Press | Contact  

About UseNewsletterMessage BoardsAction CenterAdvocateWalk to End Alzheimer’sShopDonate

Find your chapter:

search by state

In My Community
Columbia University Clinical Trials
Text Size controlsNormal font sizeMedium font sizeLarge font size

Study of Solanezumab for mild Alzheimer’s disease (LZAX STUDY): 
We are recruiting men and women between the ages of 55-90 years old with mild Alzheimer’s disease.  This study will investigate whether a medication called solanezumab given intravenously will slow the decline in thinking and function in persons with mild AD.  For additional information, please contact Evelyn Dominguez 212-305-2371.

Dominantly Inherited Alzheimer Network Trials Unit ( DIAN-TU) Study: 
We are recruiting men and women between the ages of 18-80 years old, who are either known to have an Alzheimer’s disease-causing mutation, or who are at-risk for such a mutation because they are the child or sibling of an affected individual with a known mutation, but are unaware of their genetic status.  Participants will be eligible for enrollment in this DIAN-TU-001 study if they are between 15 years younger to 10 years older than the age of onset of their affected parent.  This study accepts people with and without mild memory complaints.  For additional information, please contact Evelyn Dominguez 212-305-2371.

Clinical Study of a Potential Treatment for Cerebral Amyloid Angiopathy:
This is a clinical research study of an investigational compound being studied to see if it can slow the progression and treat the symptoms of probable Cerebral Amyloid Angiopathy (CAA).  We are recruiting men and women between the ages of 55-80 years old who have a diagnosis of probable CAA, and do not have a co-morbid diagnosis of Alzheimer’s Disease.  For additional information, please contact Evelyn Dominguez 212-305-2371. 

Study of Tolcapone for Frontotemporal Dementia
This study will test if a medication called tolcapone (Tasmar®) can improve the symptoms of frontotemporal dementia (FTD). It will also test the utility with FTD scan called fMRI for detecting changes that occur in the brain when a medication reduces symptoms and the effect of a common genetic variant on the symptoms of FTD. Men and women who have been diagnosed with FTD and are 40 to 85 years old may be eligible to participate.  For more information, please contact Masood Manoochehri at (212) 305-5710

Olfactory Deficits and Improved Cognition on Donepezil in Cognitively Impaired Elderly
Difficulties in smell, or olfaction, are known to occur in patients with Alzheimer's disease and precede the clinical diagnosis.  This study aims to evaluate if changes in odor identification deficits may be a clinically simple, relatively inexpensive, predictor of cognitive improvement with standard acetylcholinesterase inhibitor treatment. Both patients with Mild Cognitive Impairment and patients with Probable Alzheimer’s Disease are eligible for this study. Participants will be treated and tested and followed for one year. For more information, call Jennifer Ferrar at 212-543-5176.

Pilot Lithium Treatment Study of Agitation and Psychosis in Alzheimer's Disease 
This study aims to evaluate changes in agitation/aggression and psychosis in people with Alzheimer's Disease who receive 12 weeks of open treatment with Lithium.  People who have failed to respond to other medications may be eligible for this study.  Participants will receive a psychiatric assessment and will be evaluated with neuropsychological testing during the 12 week trial.  Participants will be closely monitored by study physicians and research staff to assess the changes over the course of the study.  For more information, please contact Kristina D’Antonio (212) 543-5956.

Antidepressant Treatment Studies for Combined Depression and Memory Complaints.
We are conducting medication treatment research studies for individuals age 55+ with both depression and mild memory and/or concentration difficulties.  The studies offer neuropsychological testing for memory and psychiatric evaluation of mood.  Treatment is provided for eligible individuals at no cost for at least 6 months. For more information, please contact Kristina D’Antonio (212) 543-5956.

 

OTHER STUDIES

ENROLL
ENROLL-HD is a world-wide initiative to learn more information about Huntington's disease by evaluating individuals who are part of an HD family.  Ultimately, information learned from this study may help in the development of future experimental drug studies aimed at slowing or postponing HD disease onset and progression.  All individuals diagnosed with HD, and individuals age 18 and older from an HD family, regardless of genetic testing status are eligible to participate.  For more information, please contact Paula Wasserman at (212) 305-4597 or email pl2032@columbia.edu.

CHAMPS
In this observational study, people with a diagnosis of Huntington's disease or at-risk for Huntington's disease are asked to perform three motor tasks: grasping an object, tapping on a computer keyboard and walking.  The purpose of this study is to learn more about motor and functional changes in individuals with HD.  The study visit will take approximately 1.5 hours, once every year for three years.  For more information, please contact Dr. Ashwini Rao at (212) 305-1647.

Risk Factors for Frontotemporal Dementia
This study hopes to learn about genetic and non-genetic factors that may be involved in FTD. We will use information from clinical testing, neuropsychological testing, blood DNA, and MRI imaging to ascertain subtypes of FTD, and to find genes that might be associated with these subtypes. This study invites persons diagnosed with FTD or related disorders, as well as unaffected family members, to participate.  For more information, please contact Masood Manoochehri at (212) 305-5710.

Late Onset Alzheimer Disease Study (LOAD)
The purpose of this study is to identify genes that may increase the risk for developing Alzheimer's disease (AD). We are seeking families with at least two living siblings diagnosed with AD who are 60 years or older.  For more information, please contact Pedro Mena (212) 305-2309.

Dominantly Inherited Alzheimer Network (DIAN)
The main objective of this study is to learn about brain changes that may occur on people who carry a genetic mutation which causes early onset Alzheimer disease. These participants will receive an annual follow up before they present any symptoms and includes evaluations, mental status testing, MRI and PET scans, blood assays with genetic studies and assays of cerebrospinal fluids.  For more information, please contact Dolly Reyes-Dumeyer (212) 305-5953.

The Study of Alzheimer Disease in Caribbean Hispanic Families (EFIGA)
The purpose of this study is to identify genes that may increase the risk for developing Alzheimer's disease (AD). We are seeking families and/or individuals who are 60 years or older, with or without memory problems.  For more information, please contact Angel Piriz (212) 305-2309.

Exploring Cognitive Aging Using Reference Ability Neural Networks
We are investigating cognitive aging by using functional MRI (fMRI) imaging to identify brain networks that govern performance on a variety of cognitive tests. We are looking for healthy volunteers from the ages of 20-80.   Participants will be screened for eligibility, and once enrolled, will undergo two MRI scans and two brief interviews.  For more information, contact Daniel Barulli at 212-305-1879 ordjb2168@columbia.edu

Aging, Control, and Exercise
The purpose of this study is to examine the effects of aerobic exercise on cognition between older and younger adults using functional MRI (fMRI) imaging techniques. We are recruiting healthy volunteers from the ages of 25-50 and 50-65. For more information, please contact Manzeeza Dawood at 718-710-4635 or md2811@columbia.edu

Cognitive Control and Physical Exercise: A Multi-Modal Intervention
The purpose of this study is to examine the effects of physical exercise and a computer-cognitive intervention on thinking and executive functioning in healthy older adults. We are currently recruiting healthy volunteers from the ages of 60-75 to participate in this study. This study involves brain imaging.  For more information, please contact Manzeeza Dawood at 718-710-4635 or md2811@columbia.edu

*********************************************************************************************************
Brain Donation Program: “Give the Gift of Knowledge” 
Brain donation allows valuable information to be obtained regarding normal aging and diseases that affect memory. This information may be useful towards the goal of developing more effective treatment strategies.  For more information, please contact Arlene Lawton, RN at 212-305-9086.

*********************************************************************************************************
Lucy G. Moses Center for Memory and Behavioral Disorders
Changes in memory and thinking abilities can occur from a variety of conditions, not just Alzheimer’s disease. Taub Institute specialists offer a thorough multidisciplinary evaluation of memory and thinking difficulties. We are located at The Neurological Institute, Columbia University Medical Center, 710 West 168th Street, New York.  For appointments, please call 212-305-6939.



 

Alzheimer's Association

Our vision is a world without Alzheimer's
Formed in 1980, the Alzheimer's Association is the world's leading voluntary health organization in Alzheimer's care, support and research.